AE Wealth Management LLC raised its stake in shares of Kadmon Holdings Inc (NYSE:KDMN) by 52.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 532,855 shares of the company’s stock after buying an additional 184,364 shares during the quarter. AE Wealth Management LLC owned about 0.41% of Kadmon worth $1,098,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of KDMN. Vivo Capital LLC boosted its position in Kadmon by 20.6% during the 1st quarter. Vivo Capital LLC now owns 12,606,605 shares of the company’s stock worth $33,281,000 after acquiring an additional 2,152,060 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Kadmon during the 1st quarter worth approximately $4,397,000. Millennium Management LLC acquired a new position in Kadmon during the 4th quarter worth approximately $873,000. Marshall Wace LLP raised its stake in shares of Kadmon by 343.1% during the 1st quarter. Marshall Wace LLP now owns 147,362 shares of the company’s stock worth $389,000 after purchasing an additional 114,108 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of Kadmon by 1.6% during the 4th quarter. BlackRock Inc. now owns 6,874,443 shares of the company’s stock worth $14,299,000 after purchasing an additional 105,874 shares in the last quarter. Institutional investors own 75.58% of the company’s stock.
KDMN opened at $2.41 on Monday. The company has a current ratio of 2.99, a quick ratio of 3.85 and a debt-to-equity ratio of 0.45. The firm has a market cap of $315.01 million, a price-to-earnings ratio of -2.34 and a beta of 2.09. Kadmon Holdings Inc has a 52-week low of $1.63 and a 52-week high of $4.39. The stock’s fifty day moving average is $2.29.Kadmon (NYSE:KDMN) last posted its earnings results on Monday, August 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.46 million. Kadmon had a negative net margin of 3,974.23% and a negative return on equity of 96.96%. As a group, equities analysts anticipate that Kadmon Holdings Inc will post -0.37 EPS for the current year.
A number of brokerages have recently issued reports on KDMN. Zacks Investment Research cut Kadmon from a “buy” rating to a “hold” rating in a research note on Saturday, July 27th. ValuEngine upgraded Kadmon from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Oppenheimer began coverage on Kadmon in a research note on Wednesday, June 26th. They issued an “outperform” rating and a $6.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $7.93.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington’s disease.
Further Reading: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for Kadmon Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kadmon and related companies with MarketBeat.com’s FREE daily email newsletter.